A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes

  • End date
    Aug 18, 2026
  • participants needed
  • sponsor
    Novo Nordisk A/S
Updated on 22 November 2020
Novo Nordisk
Primary Contact
Novo Nordisk Investigational Site (1.9 mi away) Contact
+233 other location
hypoglycemic agents


This study will look at the long-term effects of semaglutide (active medicine) on diabetic eye disease when compared to placebo (dummy medicine). The study will be performed in people with type 2 diabetes. Participants will either get semaglutide or placebo in addition to their diabetes medicines - which treatment the participant gets is decided by chance. Participants will inject the study medicine using a pen-injector. The medicine must be injected in a skin fold in the stomach, thigh or upper arm once a week. The study will last for 5 years.

Treatment semaglutide, Placebo (semaglutide)
Clinical Study IdentifierNCT03811561
SponsorNovo Nordisk A/S
Last Modified on22 November 2020

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.


Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have any of these conditions: Diabetes Mellitus, Type 2 or Diabetes Mellitus Type 2 or NIDDM?
Do you have any of these conditions: type 2 diabetes mellitus or type ii diabetes or Diabetes Mellitus Type 2 or type 2 diabetes or diabetes type 2 or noninsulin-dependent diabetes mellit...?
Do you have any of these conditions: Diabetes Mellitus, Type 2 or diabetes type 2 or Diabetes Mellitus Type 2 or type 2 diabetes or NIDDM or type 2 diabetes mellitus or noninsulin-depende...?
Male or female, age greater than or equal to 18 years at the time of signing informed consent
Diagnosed with type 2 diabetes mellitus
HbA1c of 7.0-10.0% (53-86 mmol/mol) (both inclusive)
Eye inclusion criteria (both eyes must meet all criteria)
Early Treatment Diabetic Retinopathy Study (ETDRS) level of 10-75 (both inclusive) evaluated by fundus photography and confirmed by central reading centre
No ocular or intraocular treatment for diabetic retinopathy or diabetic macular oedema six months prior to the day of screening
No anticipated need for ocular or intraocular treatment for diabetic retinopathy or diabetic macular oedema within three months after randomisation
Best-corrected visual acuity greater than or equal to 30 letters using the ETDRS visual acuity protocol
No previous treatment with pan-retinal laser photocoagulation
No substantial non-diabetic ocular condition that, in the opinion of the ophthalmologist, would impact diabetic retinopathy or diabetic macular oedema progression during the trial
No substantial media opacities that would preclude successful imaging

Exclusion Criteria

Any of the following: myocardial infarction, stroke, hospitalization for unstable angina pectoris or transient ischaemic attack within the past 60 days prior to the day of screening
Planned coronary, carotid or peripheral artery revascularisation known on the day of screening
Subjects presently classified as being in New York Heart Association (NYHA) Class IV
Renal impairment measured as estimated Glomerular Filtration Rate (eGFR) value of eGFR less than 30 ml/min/1.73 m^2
Personal or first degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma
Presence or history of malignant neoplasms within the past 5 years prior to the day of screening. Basal and squamous cell skin cancer and any carcinoma in-situ are allowed
Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using highly effective contraceptive methods
Concurrent treatment with any GLP-1 receptor agonist or DPP-4 inhibitor from randomisation
Receipt of any investigational medicinal product within 30 days before screening
Previous participation in this trial. Participation is defined as randomisation
Known or suspected hypersensitivity to trial products or related products
Any disorder, which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.
Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more
Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more
Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer


user name

Annotated by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No made yet